Missouri and Eli Drinkwitz have agreed to a six-year contract that will push the football coach's average compensation to $10.75 million annually and likely end any speculation that he could leave for ...

Eli Manning is a semifinalist for the Hall of Fame once again. The former Giants quarterback is among the 26 candidates for the class of 2026 who advanced to the semifinalist portion of the voting in ...

The booming market for weight-loss drugs has propelled Eli Lilly LLY-0.41%decrease; red down pointing triangle to become the first pharmaceutical company to hit $1 trillion in market capitalization, ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

College football's coaching carousel is spinning wildly in the SEC and elsewhere this season and Missouri coach Eli Drinkwitz has been linked to various openings. Rumored to be a candidate for Florida ...

TRENTON Lakewood Ponzi schemer Eliyahu "Eli" Weinstein, freed from custody when President Trump commuted his 24-year prison term for defrauding $230 million from investors, has now been sentenced to ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of Seoul-based ABL Bio, after it struck a $2.6 billion licensing and joint research deal with Eli Lilly for its bispecific antibody ...

“Ice Cream Man,” Eli Roth‘s chilling upcoming movie that the horror and slasher master described as his “most terrifying and insane film to date,” has unveiled its first look image and cast. The film ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 12.52% on an annualized basis producing an average annual return of 24.91%. Currently, Eli Lilly has a market capitalization ...

Eli Lilly (LLY) has reached a research and licensing agreement worth up to $1.2B with SanegeneBio to develop and commercialize RNAi therapeutics for metabolic diseases, the Boston, Massachusetts-based ...